ES2135165T3 - Procedimiento para la preparacion de loracarbef monohidratado. - Google Patents

Procedimiento para la preparacion de loracarbef monohidratado.

Info

Publication number
ES2135165T3
ES2135165T3 ES96301303T ES96301303T ES2135165T3 ES 2135165 T3 ES2135165 T3 ES 2135165T3 ES 96301303 T ES96301303 T ES 96301303T ES 96301303 T ES96301303 T ES 96301303T ES 2135165 T3 ES2135165 T3 ES 2135165T3
Authority
ES
Spain
Prior art keywords
loracarbef
procedure
compound
formula
monohidratado
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96301303T
Other languages
English (en)
Inventor
William Carl Henning
Theodore R Stout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2135165T3 publication Critical patent/ES2135165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/14—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
    • C07D463/16—Nitrogen atoms
    • C07D463/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D463/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D463/22—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA INVENCION ESTA DIRIGIDO A UN SOLVATO DE ANHIDRATO CRISTALINO DE LORACARBEF, Y TAMBIEN A UN PROCEDIMIENTO PARA PREPARAR UNA FORMA DE MONOHIDRATO CRISTALINO DEL COMPUESTO DE LA FORMULA I QUE IMPLICA SECAR UNA FORMA DE ISIPROPANOLATO CRISTALINO DEL COMPUESTO DE LA FORMULA I A UNA TEMPERATURA DE APROXIMADAMENTE 50 A 100 GRADOS CENTIGRADOS PARA PROPORCIONAR UNA FORMA DE ANHIDRATO CISTALINO DEL COMPUESTO DE LA FORMULA I; Y EXPONER EL ANHIDRATO CRISTALINO AL COMPUESTO DE LA FORMULA I A UNA HUMEDAD RELATIVA DE APROXIMADAMENTE 90 A 100%.
ES96301303T 1995-03-01 1996-02-27 Procedimiento para la preparacion de loracarbef monohidratado. Expired - Lifetime ES2135165T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/396,948 US5580977A (en) 1995-03-01 1995-03-01 Process for preparing loracarbef monohydrate

Publications (1)

Publication Number Publication Date
ES2135165T3 true ES2135165T3 (es) 1999-10-16

Family

ID=23569249

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96301303T Expired - Lifetime ES2135165T3 (es) 1995-03-01 1996-02-27 Procedimiento para la preparacion de loracarbef monohidratado.

Country Status (28)

Country Link
US (1) US5580977A (es)
EP (1) EP0729959B1 (es)
JP (1) JPH11501032A (es)
KR (1) KR19980702666A (es)
CN (1) CN1061349C (es)
AR (1) AR002709A1 (es)
AT (1) ATE184006T1 (es)
AU (1) AU694639B2 (es)
BR (1) BR9607308A (es)
CA (1) CA2213812A1 (es)
CO (1) CO4700429A1 (es)
CZ (1) CZ272897A3 (es)
DE (1) DE69603995T2 (es)
DK (1) DK0729959T3 (es)
ES (1) ES2135165T3 (es)
GR (1) GR3031947T3 (es)
HU (1) HUP9702151A3 (es)
IL (1) IL117228A (es)
NO (1) NO308471B1 (es)
NZ (1) NZ304534A (es)
PE (1) PE28097A1 (es)
PL (1) PL322111A1 (es)
RU (1) RU2160261C2 (es)
SI (1) SI0729959T1 (es)
TR (1) TR199700877T1 (es)
TW (1) TW330205B (es)
WO (1) WO1996026942A1 (es)
ZA (1) ZA961341B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222614T3 (es) 1997-11-12 2005-02-01 Mitsubishi Chemical Corporation Derivados de purina y medicina que los contiene como ingrediente activo.
DE60006663T2 (de) 1999-05-11 2004-10-07 Mitsubishi Chem Corp Dihydrat eines purinderivates, medikamente die dieses als aktiven wirkstoff enthalten und zwischenprodukte zu dessen herstellung
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
WO2004046142A1 (en) * 2002-11-21 2004-06-03 Ranbaxy Laboratories Limited Monohydrate solvates of loracarbef

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502663A (en) * 1969-04-21 1970-03-24 Lilly Co Eli Crystalline cephalosporin,method for its manufacture
US3531481A (en) * 1969-04-21 1970-09-29 Lilly Co Eli Method for manufacture of crystalline cephalosporin
US4775751A (en) * 1985-06-03 1988-10-04 Eli Lilly & Company Process for cephalexin hydrochloride alcoholates
DD273634A5 (de) * 1987-10-06 1989-11-22 ����@�����@�����@����k�� Verfahren zur herstellung eines kristallinen monohydrats eines 1-carbacephalosporins
CA2002596A1 (en) * 1988-11-14 1990-05-14 Thomas M. Eckrich Hydrates of b-lactam antibiotic
US4977257A (en) * 1988-11-14 1990-12-11 Eli Lilly And Company DMF solvates of a β-lactam antibiotic
US5352782A (en) * 1993-06-04 1994-10-04 Eli Lilly And Company Process for preparing crystalline β-lactam monohydrate
US5374719A (en) * 1993-06-04 1994-12-20 Eli Lilly And Company Process for converting loracarbef dihydrate to loracarbef monohydrate
US5399686A (en) * 1993-06-04 1995-03-21 Eli Lilly And Company Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate

Also Published As

Publication number Publication date
IL117228A (en) 2000-12-06
GR3031947T3 (en) 2000-03-31
CN1061349C (zh) 2001-01-31
IL117228A0 (en) 1996-06-18
HUP9702151A3 (en) 2001-01-29
WO1996026942A1 (en) 1996-09-06
CO4700429A1 (es) 1998-12-29
RU2160261C2 (ru) 2000-12-10
NZ304534A (en) 1998-09-24
PE28097A1 (es) 1997-08-20
NO308471B1 (no) 2000-09-18
TR199700877T1 (xx) 1998-02-21
PL322111A1 (en) 1998-01-05
AU5174296A (en) 1996-09-18
EP0729959B1 (en) 1999-09-01
MX9706606A (es) 1997-11-29
CA2213812A1 (en) 1996-09-06
EP0729959A1 (en) 1996-09-04
ATE184006T1 (de) 1999-09-15
ZA961341B (en) 1997-08-20
HUP9702151A2 (hu) 1998-07-28
SI0729959T1 (en) 1999-12-31
DK0729959T3 (da) 1999-12-13
DE69603995D1 (de) 1999-10-07
KR19980702666A (ko) 1998-08-05
DE69603995T2 (de) 2000-01-20
US5580977A (en) 1996-12-03
CN1182429A (zh) 1998-05-20
CZ272897A3 (cs) 1998-01-14
AU694639B2 (en) 1998-07-23
NO973835L (no) 1997-08-20
NO973835D0 (no) 1997-08-20
BR9607308A (pt) 1997-11-25
JPH11501032A (ja) 1999-01-26
TW330205B (en) 1998-04-21
AR002709A1 (es) 1998-04-29

Similar Documents

Publication Publication Date Title
DE69830504D1 (de) Antithrombotische mitteln
ATE306261T1 (de) Antithrombosemittel
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
PT1078923E (pt) Processo para a preparacao de derivados de benzotiofeno
WO2001072708A3 (en) OXINDOLE INHIBITORS OF FACTOR Xa
PT1064281E (pt) Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais
ES2135165T3 (es) Procedimiento para la preparacion de loracarbef monohidratado.
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2
DK0652879T3 (da) 1-Azaadamantanderivater som 5-HT4-agonister eller -antagonister og/eller 5-HT3-antagonister
NO940018D0 (no) Fremgangsmaate for fremstilling av svovelholdige imidazolderivater
FI896251A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyratsolopyridiinijohdannaisten valmistamiseksi
ATE170861T1 (de) Antibiotische carbapenemderivate
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
ID26809A (id) Senyawa-senyawa turunan sianoiminokuinoksalin
ES2150149T3 (es) Derivados de 17-beta-(2-oxo-tetrahidrofuran-4-il)-tio-androstano (tioderivados de 17-beta-(lactona del acido gamma-butirico)) para el tratamiento de la inflamacion, composiciones farmaceuticas y un procedimiento para la produccion de los mismos.
ES519530A0 (es) Procedimiento para la preparacion de tienobenzodiazepinonas sustituidas.
ES2089439T3 (es) Nuevos derivados amidicos de 1-amino-octahidro-pirido-(2,1-c)-(1,4)-oxazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR014135A1 (es) Profarmacos de lobucavir y metodos de uso
ES534033A0 (es) Procedimiento para la preparacion de derivados de acridanona.
ES2113382T3 (es) Derivados de azetidinona y procedimiento para producir derivados de azetidinona y cefalosporina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 729959

Country of ref document: ES